Pushing the boundaries of somatic copy-number variation detection: advances and challenges
At the 2014 Annual Meeting of the American Society of Human Genetics in San Diego, thousands of attendees crammed into a large, overcrowded auditorium to listen to the invited session on copy-number variation (CNV). There, thought leaders such as Mark Gerstein and Steve McCarroll delivered talks on approaches to detect and interpret novel CNVs. One big takeaway point from that morning: new technologies and computational methods are two main driving forces behind recent advancements. On one hand, emerging technologies such as long-read sequencing [1] , single-cell sequencing [2] , droplet digital PCR [3] , and nanochannel arrays [4] generate much excitement. On the other, refinement of computational techniques to normalize sequencing data and detect CNV at greater resolution allows for large-scale CNV studies, especially as more sequencing data are being generated and becomes available. In this issue of Annals of Oncology, Favero et al. [5] take the CNV calling algorithm one step further. Their method, Sequenza, not only improves the detection accuracy of sample purity, tumor ploidy, and absolute CNV calls, but also provides allele-specific copy-number estimates. This will allow for more comprehensive understanding of the functional impact of copy-number alteration.
In the course of cancer evolution, normal cells acquire and accumulate aberrations in their genomes. Among the types of genetic aberrations, CNVs affect the largest fraction of the genome [6, 7] , with events ranging in size from a single exon to the whole genome [8] . CNVs are signatures of genome instability and deregulation, and duplication of oncogenes has been shown to cause several types of cancer [6] . In a recent 'pan-cancer' survey of CNVs, whole-genome doubling is observed in 37% of cancers and is correlated with other events such as TP53 mutations and CCNE1 alterations [9] .
Next-generation sequencing, especially exome sequencing, has become an indispensable tool in the study of cancer biology. Detection of CNVs from sequencing data is enabled by computational approaches that normalize read counts and identify CNV regions. Several methods have been published over the past few years. Largely they can be characterizes by the intended application (germline, somatic), sequencing technology (whole genome, whole exome, targeted), type of samples (one genome, several genomes, paired tumor-normal), and detection strategy (read depth, paired-end, split read, assembly) (for review, see [10] and [11] ).
In the context of cancer research, methods that use tumornormal paired samples are most suitable for detecting somatic CNVs because (i) they exclude germline CNVs from consideration and (ii) the comparison of reads from the same region reduces positional biases such as GC content and uniqueness of the sequences. Generally, these methods proceed by taking the ratio of normalized read counts between tumor and normal samples in a given window. In theory, the ratio of 1 represents no copy-number change; the ratio of 1.5 presents one copy gain; and the ratio of 0.5 represents one copy loss (assuming diploid genome). However, because most tumor biopsy samples are mixtures of normal and cancer cells, the read ratios tend to deviate from the expected values of 0.5 or 1.5 toward 1 (the 'null'), thus reducing the power of detection. Taking into Annals of Oncology editorials account sample purity (cellularity) is key to accurate detection of somatic CNVs.
Aneuploidy of cancer genomes presents another complicating factor. Using the read ratio alone is not sufficient to estimate 'absolute' copy numbers, as the baseline of the read ratio corresponds to the average ploidy of the tumor sample, which is often unknown. Incorporation of the fraction of nonreference allele (B allele frequency or BAF) can reveal the tumor ploidy, because different tumor ploidy exhibits distinct BAF signatures. So far, only a handful of methods, such as Patchwork [12] , absCN-SEQ [13] , ABSOLUTE [14] , and now Sequenza [5] , use both tumor purity and ploidy to identify absolute copy numbers.
As discussed by the authors, what sets Sequenza apart from ABSOLUTE and absCN-SEQ is its ability to detect allele-specific CNV. Recent studies have observed preferential amplification of certain alleles in cancer [15, 16] . Sequenza utilizes allelic imbalance at heterozygous sites, as observed through BAF, to 'phase' copy numbers. To my knowledge, Patchwork is the only other sequencing-based method that achieves this level of resolution.
One last and largely unsolved challenge of somatic CNV detection is clonal heterogeneity among tumor cells. All existing methods assume that the tumor cells are monoclonal. This assumption is likely wrong as genetic heterogeneity is an important aspect of tumor development and evolution [17] . While subclonal diversity can be estimated by single-cell sequencing [18] , it is not a scalable solution. With deeply sequenced mutations and local copy-number context, one can decipher clonal distribution within a tumor sample [19, 20] , but this is yet to be incorporated into CNV detection algorithm.
While new CNV detection methods help advance our understanding of the cancer genomes, they also create a daunting task for researchers to choose a method for their studies. Although some benchmarks, such as array-based CNV calls on the same set of samples or computer simulation, were used to evaluate the methods, it is unclear how well they capture the complexity of real tumor samples. A comparative study of CNV detection methods shows that while these methods can detect CNV, the concordance and reproducibility of the results is quite low [21] . Without a gold standard, the choice of CNV detection method relies on external factors such as ease of use or reputation of the authors. Thus, it is imperative that the research community defines a gold standard dataset, simulated or real, which captures the complexity of cancer genome for evaluation and development of new methods. Perhaps this could be a topic for next year's ASHG session on CNV.
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